Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

*Stroke Vasc Neurol*

**SUPPLEMENTAL MATERIAL**

**Stroke and Vascular Neurology**

**Retinal microvascular signs and recurrent vascular events in patients with TIA or minor stroke**

1

Supplemental table 1. Baseline characteristics by fundus groups

| | No or mild vascular retinopathy | | Moderate vascular retinopathy | | Vascular retinopathy with vessel rarefaction | |
|---|---|---|---|---|---|---|
| | Yes (n=155) | No (n=567) | Yes (n=473) | No (n=249) | Yes (n=94) | No (n=628) |
| Age (years), mean (±SD) | 64 (±11) | 70 (±9) | 70 (±10) | 67 (±11) | 72 (±7) | 68 (±10) |
| Sex, n (%) | | | | | | |
| Female | 59 (38.1) | 192 (33.9) | 160 (33.8) | 91 (36.5) | 32 (34.0) | 219 (34.9) |
| Male | 96 (61.9) | 375 (66.1) | 313 (66.2) | 158 (63.5) | 62 (66.0) | 409 (65.1) |
| Study arm, n (%) | | | | | | |
| Conventional care | 67 (56.8) | 285 (50.3) | 235 (49.7) | 114 (45.8) | 47 (50.0) | 305 (51.4) |
| Intensified care | 88 (43.2) | 282 (49.7) | 238 (50.3) | 135 (54.2) | 47 (50.0) | 323 (48.6) |
| BMI (kg/m$^2$), mean (±SD) | 29 (±5) | 28 (±4) | 28 (±4) | 28 (±5) | 27 (±4) | 28 (±4) |
| ABCD2, median (IQR) | 4 (3-5) | 4 (4-5) | 4 (4-5) | 4 (4-5) | 5 (4-6) | 4 (4-5) |
| NIHSS, median (IQR)† | 1 (0-2) | 1 (0-2) | 1 (0-2) | 1 (0-2) | 1 (0-2) | 1 (0-2) |
| Carotid surgery, n (%) | 5 (3.2) | 17 (3.0) | 13 (2.7) | 9 (3.6) | 4 (4.3) | 18 (2.9) |
| Vascular risk factors, n (%) | | | | | | |
| Hypertension | 127 (81.9) | 513 (90.5) | 423 (89.4) | 217 (87.1) | 90 (95.7) | 550 (87.6) |
| Diabetes mellitus | 41 (26.5) | 133 (23.5) | 116 (24.5) | 58 (23.3) | 17 (18.1) | 157 (25.0) |
| Atrial fibrillation | 27 (17.4) | 100 (17.6) | 88 (18.6) | 39 (15.7) | 12 (12.8) | 115 (18.3) |
| Smoking | 43 (27.7) | 84 (14.8) | 72 (15.2) | 55 (22.1) | 12 (12.8) | 115 (18.3) |
| Index event, n (%) | | | | | | |
| TIA | 71 (45.8) | 255 (45.0) | 223 (47.1) | 103 (41.4) | 32 (34.0) | 294 (46.8) |
| Minor stroke | 84 (54.2) | 312 (55.0) | 250 (52.9) | 146 (58.6) | 62 (66.0) | 334 (53.2) |
| Stroke etiology, n (%) | | | | | | |
| Large vessel atherosclerosis | 16 (10.3) | 51 (9.0) | 40 (8.5) | 27 (10.8) | 11 (11.7) | 56 (8.9) |
| Cardioembolism | 30 (19.4) | 103 (18.2) | 88 (18.6) | 45 (18.1) | 15 (16.0) | 118 (18.8) |
| Small vessel disease | 8 (5.2) | 51 (9.0) | 39 (8.2) | 20 (8.0) | 12 (12.8) | 47 (7.5) |
| Other etiology | 0 (0) | 11 (1.9) | 11 (2.3) | 0 (0) | 0 (0) | 11 (1.8) |
| Undetermined cause | 101 (65.2) | 351 (61.9) | 295 (62.4) | 157 (63.1) | 56 (59.6) | 396 (63.1) |
| Previous vascular event, n (%) | | | | | | |
| TIA‡ | 9 (5.8) | 31 (5.7) | 24 (5.3) | 16 (6.6) | 7 (7.6) | 33 (5.5) |
| Stroke§ | 25 (16.2) | 92 (16.5) | 70 (15.1) | 47 (19.0) | 22 (23.7) | 95 (15.4) |
| Myocardial infarction‖ | 12 (7.7) | 45 (8.1) | 37 (7.9) | 20 (8.1) | 8 (8.6) | 49 (7.9) |

†Data available for 720 patients
‡Data available for 696 patients
§Data available for 710 patients
‖Data available for 714 patients
SD, standard deviation; BMI, body mass index; IQR, interquartile range; NIHSS, National Institute of Health stroke scale; TIA, transient ischemic attack.

Supplemental table 2. Cox proportional hazards for bivariate hazard ratios

| | Composite events (N=109) | | Recurrent stroke (N=74) | | Acute coronary syndrome (N=20) | | Vascular death (N=15) | |
|---|---|---|---|---|---|---|---|---|
| | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value |
| Age | 1.04 (1.01-1.06) | 0.001 | 1.04 (1.01-1.07) | 0.004 | 1.03 (0.98-1.09) | 0.230 | 1.03 (0.97-1.09) | 0.398 |
| Sex | 0.93 (0.62-1.38) | 0.703 | 0.95 (0.58-1.53) | 0.819 | 0.65 (0.23-1.78) | 0.396 | 1.28 (0.46-3.59) | 0.640 |
| Study arm (conventional care) | 1.08 (0.74-1.57) | 0.699 | 1.02 (0.64-1.61) | 0.941 | 1.53 (0.63-3.75) | 0.351 | 0.90 (0.33-2.48) | 0.835 |
| BMI (kg/m$^2$) | 1.00 (0.96-1.04) | 0.988 | 0.99 (0.94-1.04) | 0.747 | 1.00 (0.90-1.10) | 0.930 | 1.05 (0.94-1.16) | 0.417 |
| ABCD2 | 1.16 (0.99-1.36) | 0.062 | 1.27 (1.05-1.54) | 0.014 | 1.04 (0.72-1.52) | 0.821 | 0.86 (0.55-1.33) | 0.484 |
| NIHSS† | 1.04 (0.97-1.12) | 0.284 | 1.06 (0.97-1.15) | 0.202 | 1.01 (0.84-1.21) | 0.928 | 1.00 (0.81-1.23) | 1.000 |
| Carotid surgery | 2.06 (0.95-4.48) | 0.068 | 1.18 (0.37-3.82) | 0.780 | 6.06 (1.77-20.74) | 0.004 | 2.36 (0.31-17.98) | 0.406 |
| Vascular risk factors | | | | | | | | |
| Hypertension | 1.04 (0.54-1.99) | 0.914 | 0.96 (0.44-2.10) | 0.920 | 2.06 (0.28-15.37) | 0.483 | 0.79 (0.18-3.50) | 0.757 |
| Diabetes mellitus | 1.58 (1.06-2.35) | 0.024 | 1.47 (0.90-2.40) | 0.121 | 1.65 (0.66-4.13) | 0.287 | 2.09 (0.74-5.86) | 0.163 |
| Atrial fibrillation | 1.07 (0.63-1.83) | 0.793 | 1.41 (0.77-2.59) | 0.263 | 0.67 (0.16-2.90) | 0.594 | 0.36 (0.05-2.76) | 0.327 |
| Smoking | 1.15 (0.73-1.83) | 0.548 | 0.81 (0.44-1.51) | 0.510 | 1.87 (0.71-4.89) | 0.204 | 2.41 (0.82-7.04) | 0.109 |
| Index event (minor stroke) | 1.53 (1.04-2.27) | 0.033 | 1.28 (0.80-2.04) | 0.298 | 2.44 (0.89-6.71) | 0.084 | 2.23 (0.71-7.00) | 0.170 |
| Stroke etiology | | | | | | | | |
| Large vessel atherosclerosis | 1.45 (0.80-2.63) | 0.225 | 1.21 (0.57-2.57) | 0.615 | 4.71 (1.33-16.68) | 0.016 | 0.66 (0.09-5.10) | 0.689 |
| Cardioembolism | 1.14 (0.67-1.95) | 0.634 | 1.05 (0.54-2.03) | 0.888 | 2.77 (0.78-9.85) | 0.114 | 0.66 (0.15-2.99) | 0.592 |
| Small vessel disease | 1.05 (0.55-2.00) | 0.880 | 0.52 (0.19-1.45) | 0.210 | 5.59 (1.80-17.37) | 0.003 | 0.63 (0.08-4.88) | 0.658 |
| Other etiology | 3.73 (1.16-11.95) | 0.027 | 5.69 (1.74-18.57) | 0.004 | 0 | 0 | 0 | 0 |
| Undetermined cause | Reference | | Reference | | Reference | | Reference | |
| Previous vascular event | | | | | | | | |
| TIA‡ | 1.90 (1.01-3.55) | 0.046 | 2.39 (1.18-4.83) | 0.015 | 0 | 0 | 2.54 (0.57-11.34) | 0.223 |
| Stroke§ | 1.61 (1.03-2.51) | 0.037 | 1.38 (0.79-2.41) | 0.259 | 4.37 (1.77-10.75) | 0.001 | 0.40 (0.05-3.04) | 0.374 |
| Myocardial infarction‖ | 1.98 (1.14-3.42) | 0.015 | 1.31 (0.60-2.86) | 0.498 | 4.12 (1.48-11.45) | 0.007 | 2.89 (0.82-10.25) | 0.100 |
| **Fundus group** | | | | | | | | |
| **No or mild vascular retinopathy** | **Reference** | | **Reference** | | **Reference** | | **Reference** | |
| **Moderate vascular retinopathy** | **1.19 (0.75-1.88)** | **0.469** | **1.55 (0.86-2.78)** | **0.143** | **0.51 (0.18-1.47)** | **0.214** | **1.00 (0.31-3.21)** | **0.998** |
| **Vascular retinopathy with vessel rarefaction** | **1.40 (0.79-2.47)** | **0.248** | **1.54 (0.76-3.15)** | **0.234** | **1.64 (0.55-4.89)** | **0.374** | **0.45 (0.05-4.02)** | **0.474** |

†Data available for 720 patients
‡Data available for 696 patients
§Data available for 710 patients
‖Data available for 714 patients
HR, hazard ratio; CI, confidence intervals; BMI, body mass index; NIHSS, National Institute of Health stroke scale; TIA, transient ischemic attack.

Supplemental table 3. Post-hoc analysis: Baseline characteristics of patients with diabetes mellitus and hypertension

| | | Composite events | | Recurrent stroke | Acute coronary syndrome | Vascular death |
|---|---|---|---|---|---|---|
| | Total (n=154) | Yes (n=32) | No (n=122) | Yes (n=20) | Yes (n=7) | Yes (n=5) |
| Age (years), mean (±SD) | 69 (±10) | 70 (±11) | 69 (±9) | 71 (±12) | 68 (±10) | 70 (±9) |
| Sex, n (%) | | | | | | |
| Female | 47 (30.5) | 10 (31.3) | 37 (30.3) | 5 (25.0) | 2 (28.6) | 3 (60.0) |
| Male | 107 (69.5) | 22 (68.8) | 85 (69.7) | 15 (75.0) | 5 (71.4) | 2 (40.0) |
| Study arm, n (%) | | | | | | |
| Conventional care | 77 (50.0) | 20 (37.5) | 57 (46.7) | 13 (65.0) | 4 (57.1) | 3 (60.0) |
| Intensified care | 77 (50.0) | 12 (62.5) | 65 (53.3) | 7 (35.0) | 3 (42.9) | 2 (40.0) |
| BMI (kg/m$^2$), mean (SD) | 30 (±5) | 30 (±4) | 30 (±5) | 29 (±4) | 33 (±4) | 30 (±5) |
| ABCD2, median (IQR) | 5 (4-6) | 5 (4-6) | 5 (4-6) | 5 (4-6) | 5 (4-6) | 4 (3.5-6) |
| NIHSS, median (IQR) | 1 (0-2) | 1 (0-2) | 1 (0-2) | 1 (0-1) | 1 (1-3) | 2 (0-2.5) |
| Carotid surgery, n (%) | 7 (4.5) | 1 (3.1) | 6 (4.9) | 0 (0) | 1 (14.3) | 0 (0) |
| Vascular risk factors, n (%) | | | | | | |
| Atrial fibrillation | 21 (12.6) | 1 (3.1) | 20 (16.4) | 1 (5.0) | 0 (0) | 0 (0) |
| Smoking | 25 (16.2) | 11 (34.4) | 14 (11.5) | 5 (25.0) | 4 (57.1) | 2 (40.0) |
| Index event, n (%) | | | | | | |
| TIA | 71 (46.1) | 15 (46.9) | 56 (45.9) | 13 (65.0) | 1 (14.3) | 1 (20.0) |
| Minor stroke | 83 (54.9) | 17 (53.1) | 66 (54.1) | 7 (35.0) | 6 (85.7) | 4 (80.0) |
| Stroke etiology, n (%) | | | | | | |
| Large vessel atherosclerosis | 25 (16.2) | 5 (15.6) | 20 (16.4) | 3 (15.0) | 1 (14.3) | 1 (20.0) |
| Cardioembolism | 25 (16.2) | 4 (12.5) | 21 (17.2) | 3 (15.0) | 1 (14.3) | 0 (0) |
| Small vessel disease | 15 (9.7) | 5 (15.6) | 10 (8.2) | 1 (5.0) | 3 (42.9) | 1 (20.0) |
| Other etiology | 1 (0.6) | 0 (0) | 1 (0.8) | 0 (0) | 0 | 0 (0) |
| Undetermined cause | 88 (57.1) | 18 (56.3) | 70 (57.4) | 13 (65.0) | 2 (28.6) | 3 (60.0) |
| Previous vascular event, n (%) | | | | | | |
| TIA† | 6 (4.0) | 1 (3.3) | 5 (4.1) | 1 (5.6) | 0 (0) | 0 (0) |
| Stroke‡ | 26 (17.1) | 7 (22.6) | 19 (15.7) | 3 (15.8) | 4 (57.1) | 0 (0) |
| Myocardial infarction‖ | 19 (12.6) | 6 (18.8) | 13 (10.7) | 2 (10.0) | 2 (28.6) | 2 (40.0) |
| Fundus groups, n (%) | | | | | | |
| No or mild vascular retinopathy | 34 (22.1) | 8 (25.0) | 26 (21.3) | 2 (10.0) | 5 (71.4) | 1 (20.0) |
| Moderate vascular retinopathy | 103 (66.9) | 18 (56.3) | 85 (69.7) | 13 (65.0) | 2 (28.6) | 3 (60.0) |
| Vascular retinopathy with vessel rarefaction | 17 (11.0) | 6 (18.8) | 11 (9.0) | 5 (25.0) | 0 (0) | 1 (20.0) |

†Data available for 151 patients
‡Data available for 152 patients
‖Data available for 151 patients
SD, standard deviation; BMI, body mass index; IQR, interquartile range; NIHSS, National Institute of Health stroke scale; TIA, transient ischemic attack.

## Supplemental table 4. Secondary prevention targets at 1 year follow-up by fundus category

| | | No or mild vascular retinopathy | | | Moderate vascular retinopathy | | | Vascular retinopathy with vessel rarefaction | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | Total (n=722) | Yes (n=155) | No (n=567) | p-value | Yes (n=473) | No (n=249) | p-value | Yes (n=94) | No (n=628) | p-value |
| Systolic blood pressure (mmHg), mean (SD) | 130.4 (±14.9) | 126.8 (±15.5) | 131.4 (±14.6) | 0.002 | 131.1 (±14.5) | 129.0 (±15.5) | 0.088 | 132.5 (±15.0) | 130.1 (±14.9) | 0.158 |
| Diastolic blood pressure (mmHg), mean (SD) | 78.7 (±9.6) | 77.7 (±10.0) | 78.9 (±9.4) | 0.197 | 78.7 (±9.5) | 78.5 (±9.8) | 0.737 | 79.7 (±9.4) | 78.5 (±9.6) | 0.276 |
| Blood pressure target achieved† | 59.7% (368/616) | 67.7% (90/133) | 57.6% (278/483) | 0.035 | 59.1% (237/401) | 60.9% (131/215) | 0.659 | 50.0% (41/82) | 61.2% (327/534) | 0.053 |
| LDL (mg/dl), mean (SD) | 93.7 (±34.0) | 91.5 (±33.2) | 94.3 (±34.3) | 0.401 | 94.1 (±33.6) | 93.1 (±35.0) | 0.752 | 95.7 (±37.6) | 93.4 (±33.5) | 0.570 |
| LDL target achieved‡ | 54.5% (324/594) | 58.9% (76/129) | 53.3% (248/465) | 0.260 | 53.4% (206/384) | 56.2% (118/210) | 0.552 | 51.9% (42/81) | 55.0% (282/513) | 0.621 |
| Smoking abstinence | 88.3% (564/639) | 79.4% (108/136) | 90.7% (456/503) | 0.001 | 90.6% (378/417) | 83.8% (186/222) | 0.010 | 90.7% (78/86) | 87.9% (486/553) | 0.451 |
| HbA1c (%), mean (SD) | 5.9 (±0.8) | 6.0 (±0.9) | 5.9 (±0.8) | 0.418 | 5.9 (±0.8) | 6.0 (±0.8) | 0.810 | 5.9 (±0.7) | 6.0 (±0.8) | 0.520 |
| HbA1c target achieved§ | 95.7% (553/578) | 92.7% (115/124) | 96.5% (438/454) | 0.070 | 96.3% (364/378) | 94.5% (189/200) | 0.313 | 97.4% (74/76) | 95.4% (479/502) | 0.436 |
| Patients taking platelet inhibitors of all patients not taking oral anticoagulation | 93.9% (460/490) | 95.2% (99/104) | 93.5% (361/386) | 0.529 | 92.8% (297/320) | 95.9% (163/170) | 0.177 | 97.0% (64/66) | 93.4% (396/424) | 0.260 |
| Patients with atrial fibrillation taking oral anticoagulation | 91.2% (135/148) | 93.8 (30/32) | 90.5% (105/116) | 0.567 | 89.7% (87/97) | 94.1% (48/51) | 0.366 | 94.7% (18/19) | 90.7% (117/129) | 0.561 |
| Physical activity target achieved‖ | 21.3% (136/639) | 27.5% (38/138) | 19.6% (98/501) | 0.043 | 20.0% (83/415) | 23.7% (53/224) | 0.281 | 17.4% (15/86) | 21.9% (121/553) | 0.349 |

†<140/85 mmHg in patients who are not diabetic and <130/80 mmHg in patients who are diabetic.

‡Target for LDL was <100 mg/dl and <70 mg/dl in patients with coronary artery disease or symptomatic intracranial or extracranial artery stenosis.

§Target in patients with diabetes was less than 58·5 mmol/mol.

‖Target for physical activities (self-reported) was ≥30 min per day at least three times per week

Statistical tests used: independent t test for continuous variables and Pearson Chi square test for categorical variables.

SD, standard deviation; LDL, low density lipoprotein.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

*Stroke Vasc Neurol*

## Supplemental table 5. Secondary prevention targets at 2 year follow-up by fundus category

| | Total (N=722) | No or mild vascular retinopathy | | | Moderate vascular retinopathy | | | Vascular retinopathy with vessel rarefaction | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | | Yes (N=155) | No (N=567) | p-value | Yes (N=473) | No (N=249) | p-value | Yes (N=94) | No (N=628) | p-value |
| Systolic blood pressure (mmHg), mean (SD) | 130.0 (±16.0) | 126.8 (±15.8) | 131.1 (±15.9) | 0.015 | 130.1 (±15.8) | 130.0 (±16.3) | 0.937 | 135.1 (±15.7) | 129.2 (±15.9) | 0.005 |
| Diastolic blood pressure (mmHg), mean (SD) | 78.4 (±8.4) | 77.3 (±8.3) | 78.7 (±8.4) | 0.115 | 78.4 (±8.3) | 78.4 (±8.3) | 0.947 | 80.2 (±8.4) | 78.1 (±8.3) | 0.046 |
| Blood pressure target achieved† | 59.4% (277/466) | 65.2% (73/112) | 57.6% (204/354) | 0.156 | 60.4% (172/285) | 58.0% (105/181) | 0.616 | 46.4% (32/69) | 61.7% (245/397) | 0.017 |
| LDL (md/dl), mean (SD) | 94.6 (±34.7) | 90.4 (±32.0) | 96.0 (±35.5) | 0.140 | 95.6 (±34.9) | 93.2 (±34.5) | 0.475 | 97.9 (±38.2) | 94.1 (±34.1) | 0.412 |
| LDL target achieved‡ | 54.1% (242/447) | 56.8% (63/111) | 53.3% (179/336) | 0.523 | 53.7% (146/272) | 54.9% (96/175) | 0.807 | 51.6% (33/64) | 54.6% (209/383) | 0.655 |
| Smoking abstinence | 87.5% (443/506) | 81.8% (99/121) | 89.4% (344/385) | 0.029 | 89.6% (284/317) | 84.1% (159/189) | 0.072 | 88.2% (60/68) | 87.4% (383/438) | 0.854 |
| HbA1c (%), mean (SD) | 5.9 (±0.8) | 6.0 (±0.8) | 5.9 (±0.8) | 0.245 | 5.9 (±0.8) | 5.9 (±0.8) | 0.891 | 5.8 (±0.7) | 5.9 (±0.8) | 0.109 |
| HbA1c target achieved§ | 96.3% (418/434) | 97.1% (102/105) | 96.1% (317/330) | 0.608 | 96.3% (257/267) | 96.4% (162/168) | 0.925 | 95.2% (60/63) | 96.5% (359/372) | 0.621 |
| Patients taking platelet inhibitors of all patients not taking oral anticoagulation | 95.5% (359/376) | 95.5% (84/88) | 95.5% (275/288) | 0.990 | 94.5% (222/235) | 97.2% (137/141) | 0.223 | 100% (53/53) | 94.7% (306/323) | 0.087 |
| Patients with atrial fibrillation taking oral anticoagulation | 96.6% (113/117) | 96.8% (30/31) | 96.5% (83/86) | 0.945 | 95.8% (68/71) | 97.8% (45/46) | 0.551 | 100% (15/15) | 96.1% (98/102) | 0.435 |
| Physical activity target achieved‖ | 21.1% (108/511) | 22.1% (27/122) | 20.8% (81/389) | 0.757 | 21.7% (69/318) | 20.2% (39/193) | 0.689 | 16.9% (12/71) | 21.8% (96/440) | 0.346 |

†<140/85 mmHg in patients who are not diabetic and <130/80 mmHg in patients who are diabetic.

‡Target for LDL was <100 mg/dl and <70 mg/dl in patients with coronary artery disease or symptomatic intracranial or extracranial artery stenosis.

§Target in patients with diabetes was less than 58·5 mmol/mol.

‖Target for physical activities (self-reported) was ≥30 min per day at least three times per week

Statistical tests used: independent t test for continuous variables and Pearson Chi square test for categorical variables.

SD, standard deviation; LDL, low density lipoprotein.

Supplemental table 6. Secondary prevention targets at 3 year follow-up by fundus category

| | Total (N=722) | No or mild vascular retinopathy | | | Moderate vascular retinopathy | | | Vascular retinopathy with vessel rarefaction | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | Yes (N=155) | No (N=567) | p-value | Yes (N=473) | No (N=249) | p-value | Yes (N=94) | No (N=628) | p-value |
| Systolic blood pressure (mmHg), mean (SD) | 131.0 (±16.0) | 129.1 (±13.8) | 131.6 (±16.6) | 0.196 | 131.0 (±16.4) | 131.1 (±15.3) | 0.894 | 134.5 (±17.3) | 130.4 (±15.7) | 0.077 |
| Diastolic blood pressure (mmHg), mean (SD) | 78.7 (±9.6) | 79.2 (±8.6) | 78.6 (±9.8) | 0.599 | 78.4 (±10.1) | 79.3 (±8.7) | 0.342 | 79.5 (±8.9) | 78.6 (±9.7) | 0.500 |
| Blood pressure target achieved† | 59.6% (227/381) | 64.5% (60/93) | 58.0% (167/288) | 0.265 | 59.2% (138/233) | 60.1% (89/148) | 0.860 | 52.7% (29/55) | 60.7% (198/326) | 0.263 |
| LDL (mg/dl), mean (SD) | 97.0 (±34.4) | 95.5 (±33.7) | 97.4 (±34.6) | 0.651 | 97.6 (±34.0) | 96.1 (±35.2) | 0.684 | 96.9 (±37.8) | 97.0 (±33.9) | 0.986 |
| LDL target achieved‡ | 50.0% (185/370) | 52.9% (45/85) | 49.1% (140/285) | 0.537 | 49.1% (114/232) | 51.4% (71/138) | 0.667 | 49.1% (26/53) | 50.2% (159/317) | 0.882 |
| Smoking abstinence | 89.4% (380/425) | 82.0% (82/100) | 91.7% (298/325) | 0.006 | 91.7% (242/264) | 85.7% (138/161) | 0.053 | 91.8% (56/61) | 89.0% (324/364) | 0.512 |
| HbA1c (%), mean (SD) | 6.0 (±0.8) | 6.0 (±0.8) | 5.9 (±0.8) | 0.732 | 6.0 (±0.8) | 5.9 (±0.7) | 0.798 | 5.9 (±0.6) | 6.0 (±0.8) | 0.440 |
| HbA1c target achieved§ | 95.5% (341/357) | 93.8% (75/80) | 96.0% (266/277) | 0.386 | 95.2% (217/228) | 96.1% (124/129) | 0.677 | 100% (49/49) | 94.8% (292/308) | 0.103 |
| Patients taking platelet inhibitors of all patients not taking oral anticoagulation | 94.7% (302/319) | 94.4% (68/72) | 94.7% (234/247) | 0.923 | 94.0% (188/200) | 95.8% (114/119) | 0.489 | 97.9% (46/47) | 94.1% (256/272) | 0.290 |
| Patients with atrial fibrillation taking oral anticoagulation | 94.2% (98/104) | 96.0% (24/25) | 93.7% (74/79) | 0.663 | 95.4% (62/65) | 92.3% (36/39)) | 0.515 | 85.7% (12/14) | 95.6% (86/90) | 0.142 |
| Physical activity target achieved‖ | 19.1% (82/429) | 23.2% (23/99) | 17.9% (59/330) | 0.235 | 18.3% (49/268) | 20.5% (33/161) | 0.572 | 16.1% (10/62) | 19.6% (72/367) | 0.518 |

†<140/85 mmHg in patients who are not diabetic and <130/80 mmHg in patients who are diabetic.
‡Target for LDL was <100 mg/dl and <70 mg/dl in patients with coronary artery disease or symptomatic intracranial or extracranial artery stenosis.
§Target in patients with diabetes was less than 58·5 mmol/mol.
‖Target for physical activities (self-reported) was ≥30 min per day at least three times per week
Statistical tests used: independent t test for continuous variables and Pearson Chi square test for categorical variables.
SD, standard deviation; LDL, low density lipoprotein.